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Background. The delicate foot process architecture of
glomerular podocytes critically depends on integrin mediated
cell-glomerular basement membrane (GBM) interaction. Inte-
grin signaling via the integrin-linked kinase (ILK) is activated
in podocyte damage and associated with considerable podocyte
phenotype alterations. ILK has been shown to regulate cell fate
via nuclear interaction of b-catenin with lymphoid enhancer
factor (LEF-1) transcription factors. The aim of this study was
to elucidate the molecular mechanisms of ILK dependant phe-
notype regulation in podocytes.
Methods. ILK function was evaluated in conditionally im-
mortalized murine glomerular epithelial cells using overex-
pression of ILK and a small molecule ILK inhibitor in
puromycin/adriamycin-induced podocyte damage in vitro and
in vivo.
Results. Kinase active, but not mutant ILK induced translo-
cation of b-catenin to the cell nucleus, de novo expression of
LEF-1, and nuclear colocalization of b-catenin and LEF-1. The
role of ILK signaling in podocyte damage was evaluated using
puromycin, an agent known to cause selective proteinuria and to
increase ILK activity. The small molecular ILK inhibitor MC-5
blocked puromycin-induced nuclear translocation of b-catenin,
podocyte detachment, cell proliferation, and repression of the
slit membrane molecules P-cadherin and CD2ap. In vivo ac-
tivation of the b-catenin pathway could be shown by nuclear
colocalization of b-catenin with WT-1 in adriamycin nephropa-
thy.
Conclusion. ILK regulates podocyte cell matrix interaction,
proliferation, and slit membrane gene expression in podocyte
damage. As this pathway is amendable to pharmacologic in-
tervention, further detailed studies of in vivo ILK function in
glomerular disease appear justified.
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Glomerular diseases are the principal cause of renal
failure, and proteinuria is their hallmark. Severe protein-
uria is also considered as an indicator of poor prognosis
and may contribute to renal scarring [1]. As a component
of the filtration barrier, the podocytes are a major target
of injury and podocyte cell shape changes, including foot
process effacement and separation from the glomerular
basement membrane (GBM), are key events in progres-
sive glomerular failure [2]. The podocyte displays a highly
differentiated phenotype with a complex cellular organi-
zation critical for maintenance of the glomerular filtration
barrier. However, the molecular mechanism of disease
associated cell phenotype alterations are poorly under-
stood.
Podocytes reside outside the glomerular capillary with
their cell bodies floating freely in the urinary space. Cell
somata are anchored to the GBM via progressive cy-
toplasmic branches terminating in podocyte foot pro-
cesses. Foot processes interdigitate with their neighboring
partner to completely cover the external surface of the
glomerular capillaries [2]. The anchorage to the GMB
is mediated by a a3b1-integrin complex present in the
‘sole’ of the foot processes. The integrin heterodimers
are clustered in focal adhesions and linked to the con-
tractile structure of the podocyte cytoskeleton, contain-
ing actin, myosin, a-actinin, talin, and vinculin [3]. The
integrin complex seems to be essential for the glomeru-
lar filtration barrier since antibody-mediated blockade of
glomerular integrins results in podocyte detachment [4],
and a3-integrin knockout mice are born with a congenital
nephrotic syndrome phenotype [5].
Integrins can activate a wide range of intracellular sig-
naling pathways, even though they lack intrinsic enzy-
matic activity. Integrin ligation recruits or activates sig-
naling molecules, such as kinases, to the cytoplasmic tails
of integrins [6]. For the b 1 integrins, direct binding was
reported in vitro for talin, a-actinin, tensin, focal ad-
hesion kinase (FAK), and integrin-linked kinase (ILK)
[7].
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ILK is an ankyrin-repeat containing serine/threonine
protein kinase [7]. Its 1.8-kb transcript is widely expressed
in human tissues, such as placenta, heart, skeletal muscle,
brain, lung, liver, pancreas, and kidney [8, 9]. Two hybrid
and coimmunoprecipitation studies showed interaction
of ILK with the cytoplasmic domains of integrin b 1, b 2,
and b 3. ILK is involved in both “inside-out” and “outside-
in” integrin signaling [7]. Kinase activity is regulated by
phosphatidylinositol 3-kinase, implicating several growth
factors, such as TGF-b and insulin, in ILK activation [10].
However, ILK is not only involved in cellular control of
integrin-mediated cell-matrix interactions but also in cell
phenotype regulation. Overexpression of the active ki-
nase in epithelial cells resulted in a down-regulated E-
cadherin expression. As a consequence, cell-cell adhe-
sion was disorganized by inhibition of the homophilic E-
cadherin mediated cell-cell interaction. The subsequent
disruption of the characteristic cobblestone morphology
induced fibronectin matrix assembly, a property of mes-
enchymal cells, demonstrating ILK dependent phenotype
regulation [11].
Cell phenotype transformation is found during embry-
onic development and in several pathologic processes.
During embryogenesis, the morphogenetic effect is or-
chestrated by activation of the Wnt signaling pathway,
controlling embryonic patterning and cell-fate decisions
in a highly conserved molecular function across a wide
range of animal taxa [12]. A central feature of the canonic
Wnt signaling pathway is the stabilization of a cytoso-
lic pool of b-catenin and a translocation of b-catenin
into the nucleus, where it interacts with members of
the lymphoid enhancer factor I (LEF-1)/T-cell factor
(TCF) family of transcription factors ([13] for a current
overview of the Wnt signaling network see http://stke.
sciencemag.org/cgi/cm/CMP /5533). The activation of
this transcriptional complex serves as a master switch in
cell fate regulation [14]. Downstream components of this
pathway have been reported to function independent of
upstream Wnt signaling [15, 16].
ILK overexpression in two independent epithelial cell
lines resulted in a nuclear localization of b-catenin and
in an increased transcriptional activation of LEF-1, indi-
cating its implication with these components of the Wnt
signaling pathway [17]. Specifically, ILK up-regulates the
b-catenin transcriptional pathway via Akt/PKB phospho-
rylation and inhibition of GSK-3 dependent phosphoryla-
tion of b-catenin [10]. Unphosphorylated, free b-catenin
in the cytoplasm escapes proteolytic degradation [18] and
translocates into the nucleus, where it interacts with LEF-
1/TCF. A switch in the transcriptional program leads to
cell cycle and cell phenotype alterations, including cy-
toskeletal rearrangements and E-cadherin repression [17,
19]. In contrast to the canonic Wnt pathway, ILK induc-
tion induces sole translocation of b-catenin to the nucleus
without alterations in the b-catenin levels [17].
Recently, we have reported the activation of ILK in
proteinuric kidney diseases [20]. The aim of this study
was to define the pathway of ILK activation with the sub-
sequent phenotype regulation in podocyte damage. To
this end, downstream elements of the Wnt pathway were
analyzed, and evidence is provided that ILK activation in
podocyte damage results in significant phenotype alter-
ations.
METHODS
Cell line and culture conditions
As an in vitro model system, conditionally immor-
talized glomerular epithelial cells derived from kidneys
of adult (10-week-old) transgenic H-2Kb-tsA58 mice
harboring a temperature-sensitive SV40 large T anti-
gen under control of a interferon-c inducible promoter
were used. These cells have been shown to express
podocyte phenotype markers (i.e., WT-1, synaptopodin,
P-cadherin, and Glepp-1) under nonpermissive condi-
tions [21]. Briefly, cells were propagated under permis-
sive conditions at 33◦C with RPMI 1640 medium (Life
Technologies, Karlsruhe, Germany) supplemented with
10% fetal calf serum (Bio Whittaker, Verviers, Belgium),
100 U/mL penicillin, 100 mg/mL streptomycin and
10 U/mL mouse recombinant interferon-c (Sigma, St.
Louis, MO, USA) to enhance expression of the T anti-
gen. In order to induce differentiation, podocytes were
maintained on type I collagen (100 lg/mL; Biochrom
KG, Seromed, Berlin, Germany) coated surface at 37◦C
without interferon-c (nonpermissive conditions) for at
least 10 days. Cells at passages 10 to 16 were used for the
studies.
ILK overexpressing murine podocytes
Podocytes were transfected with a mammalian vector
containing wild-type ILK (wt-ILK) or a kinase-deficient
form of ILK with a single point mutation at amino residue
359 (Glu->Lys) of kinase subdomain VIII (mt-ILK). The
complete characterization of these cell lines is described
in detail elsewhere [20].
Isolation of nuclei from cultured cells
Cells were harvested directly into a hypotonic buffer
(5 mmol/L HEPES pH 7.6, 2 mmol/L MgCl2, 75 mmol/L
NaCl, 5 mmol/L EDTA pH 7.4) and incubated on ice
for 10 minutes. Subsequently, cells were homogenized,
and nuclei pelleted by centrifugation at 6300 rpm for
7 minutes. The pellet was resuspended in RIPA lysis
buffer (50 mmol/L Tris-HCl pH 7.4, 1% Nonidet P-40,
0.25% sodium deoxycholat, 150 mmol/L NaCl, 1 mmol/L
EGTA, 1 mmol/L Na3VO4), homogenized, and cen-
trifuged at 5000 rpm for 30 minutes. The supernatant
was used as nuclear extracts. All solutions contained
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protease inhibitors (Complete, Roche, Germany). The
quality of fractionation was assessed using tubulin (a-
tubulin, Serotec, Oxford, UK) and c-Jun (c-Jun; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) as marker
proteins for cytosolic or nuclear fractions, respectively.
Western blotting and antibodies
Whole cell extracts were harvested in RIPA lysis
buffer, and Western blotting performed as described [20].
Immune complexes were visualized using enhanced
chemiluminescence (ECL; Amersham International,
Braunschweig, Germany). The following antibodies were
used: polyclonal rabbit anti-ILK (Upstate Biotech-
nology, Lake Placid, NY, USA), monoclonal mouse
anti-b-catenin (BD Transduction Laboratories, Heidel-
berg, Germany), rabbit anti-LEF-1 (kindly provided by
Dr. J. Behrens, Erlangen, Germany), anti-P-cadherin
(R&D Systems, Wiesbaden, Germany), anti-a-tubulin
(Serotec). Densitometry of Western blots for P-cadherin
was quantified using ImageQuant software (Molecular
Dynamics, Krefeld, Germany).
Indirect immunofluorescence
Cells were grown in RPMI 1640 on collagen I-coated
glass cover slips and fixed with 2% paraformaldehyde
and 4% sucrose in phosphate-buffered saline (PBS) for
10 minutes at room temperature. Subsequently, they were
permeabilized with 0.3% Triton X-100 in PBS for 10 min-
utes. After rinsing with PBS, nonspecific binding sites
were blocked (2% FCS, 2% BSA, 0.2% fish gelatine in
PBS) for 30 minutes, followed by incubation with pri-
mary antibody prediluted in blocking solution for 60 min-
utes at room temperature. Antigen-antibody complexes
were visualized using fluorescein isothiocyanate (FITC)-
or fluorochrome (Cy2)-conjugated secondary antibodies
(Jackson Laboratories, Dianova, Hamburg, Germany)
for 1 hour. For double staining experiments, a 1-hour
sequential incubation with two primary antibodies fol-
lowed by 1-hour incubation with a mixture of labeled
secondary antibodies (Jackson Laboratories) was per-
formed. Corresponding irrelevant murine or rabbit im-
munoglobulins served as negative controls. Cover slips
were washed with PBS, rinsed in H2O, and mounted us-
ing 15% Mowiol (Calbiochem, VWR International, Bad
Soden, Germany). After overnight drying, specimens
were analyzed using a Leitz fluorescence microscope. b-
catenin distribution was visualized using a confocal laser
scanning microscope in addition to immunofluorescence
microscopy.
In vitro podocyte damage model
Podocytes were cultured on glass cover slips under non-
permissive conditions for at least 7 days to induce dif-
ferentiation. Twenty-four hours prior to the experiments
10% FCS medium was substituted for 0% to 2% FCS
medium. Five to 10 lg/mL puromycin was added to the
medium, and at distinct time intervals (0, 2, 4, 6, and
8 hours) cells were processed for immunofluorescence
or Western blotting as stated above.
To assess the ILK dependence of this process, exper-
iments were performed as described above for 8 hours,
with addition of a small molecular inhibitor of ILK (pro-
vided by Kinetek Pharmaceuticals, Vancouver, Canada)
[22].
Murine adriamycin nephropathy
To assess the relevance of b-catenin/LEF-1 activation
in in vivo podocyte damage, the murine model of adri-
amycin nephropathy was employed [23]. Male Balb/c
mice (18-21 g body weight, Charles River, Sulzfeld,
Germany) were treated with a single tail vein injection
of 13 mg/kg body weight adriamycin (ADR) and sac-
rificed at day six after dosing. At this time point, se-
vere filtration barrier failure was induced (albuminuria of
160,000 lg/mg creatinine vs. 100 lg/mg in carrier injected
controls), but glomeruli appear intact by light microscopy.
All experimental procedures were performed according
to the German animal care and ethics legislation, and had
been approved by the local authorities.
Immunohistochemistry
Immunohistochemistry was performed on 5 lm-thick
acetone-fixed kidney sections.
Slides were sequentially hydrated, incubated with the
primary polyclonal rabbit anti-WT1 antibody (c-19; Santa
Cruz Biotechnology), followed by the secondary Alexa
Fluor 568 goat antirabbit IgG (Molecular Probes, Invit-
rogen Italia SRL, S. Giuliano Milanese, Milan, Italy). Af-
ter washing, sections were then incubated with the pri-
mary monoclonal mouse anti-b-catenin antibody (BD
Biosciences, Heidelberg, Germany), followed by the sec-
ondary Alexa Fluor 488 goat antimouse IgG, highly cross
adsorbed (Molecular Probes).
Immunohistochemistry for ILK was performed with a
primary ILK antibody (BD Biosciences) followed by the
secondary Alexa Fluor 488 goat antimouse IgG, highly
cross adsorbed (Molecular Probes), demonstrating in-
creased ILK protein levels in proteinuric glomeruli of
adriamycin treated mice compared to controls (Fig. 4C).
Slides were mounted with Fluorsave aqueous mount-
ing medium (Calbiochem). Specificity of antibody
labeling was demonstrated by the lack of staining after
substituting proper control immunoglobulins for the pri-
mary antibodies. Colocalization studies were conducted
on digitized images by Q-Fluor software (Leica Italia,
Milan, Italy).
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Fig. 1. ILK-dependent subcellular localization of b-catenin and LEF-1. Localization of b−catenin and LEF-1 in normal and ILK-overexpressing
murine podocytes. (A) Control podocytes (A, D), wild-type (wt)-ILK overexpressing podocytes (B, E), and mutant (mt)-ILK overexpressing
podocytes (C, F) show distinct distribution of b-catenin and LEF-1. Indirect immunofluorescence labels b-catenin in control podocytes diffusely
in cytoplasm and at cell-contacts without nuclear staining (A). In contrast, wt-ILK overexpressing cells showed b-catenin mainly in nuclei and at
cell-cell contacts (B). b-catenin in mt-ILK cells is found at cell membrane and diffusely in cytoplasm in the perinuclear region (C). The transcription
factor LEF-1 could only be detected in a nuclear pattern (E) in wt-ILK overexpressing cells. Control and mt-ILK cells were negative for LEF-1 (D,
F). (B) Nuclear extracts were probed for b-catenin and LEF-1 by Western blotting. Wild-type-ILK overexpressing cells showed increased amounts
of nuclear b-catenin and LEF-1 protein in comparison to control and mt-ILK cells. C-jun served as loading control for nuclear proteins.
MTT proliferation assay
The assays were performed in 96-well plates (Corn-
ing, Corning, NY, USA). Five thousand cells per collagen
coated well were grown at 37◦C in phenolred-free cell cul-
ture 1640 RPMI medium (Gibco, Invitrogen, Karlsruhe,
Germany). The normal growth medium was replaced by
medium without FCS 18 hours before the treatment of the
cells. Puromycin and the small molecular ILK-inhibitor
(Kinetek Pharmaceuticals) were then added for 24 hours.
Four hours before the end of incubation time, 30 lL MTT
(stock: 5 mg/mL; Sigma, Munich, Germany) dissolved in
phenolred-free 1640 RPMI medium was added to each
well. At the end of the assay the medium was removed
and the cells were dissolved in 100 lL DMSO. Absorp-
tions were measured in a Tecan Microplate Reader Ge-
nios Plus (Crailsheim, Germany) at 540 and 620 nm (ref-
erence wavelength).
Adhesion assay
Murine podocytes were incubated at 37◦C on collagen-
coated dishes. One day before the assay, cells were starved
for 18 hours. Puromycin and MC-5 ILK inhibitor were
added for additional 24 hours. The assay was then per-
formed as formerly described in [20].
Real-time RT-PCR
The steady state mRNA expression levels of P-
cadherin, CD2AP, protocadherin, and FAT were quan-
tified using real-time reverse transcription-polymerase
chain reaction (RT-PCR) as described [24].
In brief, RNA was isolated using a silica gel-
based RNA isolation protocol (RNeasy-Mini; Qiagen,
Hilden, Germany) followed by random primed reverse
transcription.
518 de Paulo Castro Teixeira et al: Integrin-linked kinase activation in podocyte damages
β-catenin
LEF-1
Merge
Control wt-ILK mt-ILK
Fig. 2. Double labeling for b-catenin and
LEF-1. Immunofluorescences were per-
formed with control podocytes (A, D, G),
wt-ILK overexpressing cells (B, E, H),
and mt-ILK overexpressing cells (C, F, I).
Double labeling for b-catenin (A–C) and
LEF-1 (D–F) displayed a colocalization of
both molecules only in the nuclei of wt-ILK
overexpressing cells (merge; H). In contrast,
b-catenin does not colocalize with LEF-1 in
control (G) and mt-ILK (I) cells.
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Fig. 4C. (Continued)
RT-PCR was performed on TaqMan ABI 7700 Se-
quence Detection System (Applied Biosystems, Darm-
stadt, Germany) using heat-activated TaqDNA poly-
merase (Amplitaq Gold; Applied Biosystems), as pre-
viously described [24]. For all quantitative analyses the
cDNA content of each sample was compared with an-
other sample following the Ct technique [25]. All
PCR reactions were performed in duplicate. Controls
consisting of ddH2O were negative in all runs.
TaqMan reagents and the following oligonucleotide
primers (300 nmol/L) and probes (100 nmol/L) from
Applied Biosystems were used. Specific primers for
murine P-cadherin and murine GAPDH were em-
ployed. P-cadherin: sense 5′-GCTCTACCACGACGG
CAGAG -3′, antisense 5′-GCCTCATACTTCTGCGGC
TC-3′, internal probe 5′-CCTTGATGCCAACGATA
ACGCTCCG -3′. GAPDH: sense 5′-CATGGCCTTC
CGTGTTCCTA-3′, antisense 5′-ATGCCTGCTTCAC
CACCTTCT-3′, internal probe 5′- CCCAATGTGTCC
GTCGTGGATCTGA-3′. Assay-by-Desing for FAT: se-
quence: sense 5′- CCCCGAGAGGAGAAGTATAG
CT-3′, antisense 5′- ACGAAGCTGTTTCCCGTGAA-
3′, internal probe 5′- ATGCCCAGGGAGCTCA-3′.
Assay-on-demand and predeveloped TaqMan assays
were used for CD and 18S rRNA, respectively. All real-
time RT-PCR reagents were supplied by Applied Biosys-
tems.
Except for 18s rRNA, the primers were cDNA-specific
and did not amplify genomic DNA. Data shown are mean
values ± SD from two independent clones analyzed.
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Fig. 3. ILK-dependent regulation of the epithelial marker molecule
P-cadherin on mRNA and protein level. (A) Using real-time RT-PCR
primer and probes, the mRNA expression of P-cadherin and GAPDH
was determined. Expression levels are normalized to the control con-
dition ( = 1). A significant decrease in P-cadherin mRNA compared to
wt-ILK cells is seen. Two independent overexpressing clones were ana-
lyzed, and real time RT-PCR data presented as mean ± SD. (B) Whole
cell lysate was analyzed by Western blot for P-cadherin. P-cadherin pro-
tein was repressed in wt-ILK overexpressing cells compared to controls.
Statistics
Data are given as mean ± SD. Statistical analysis was
performed by using unpaired Student t test, significance
level P < 0.05.
RESULTS
Wild-type ILK overexpression leads to podocyte
phenotype alterations and induces nuclear
translocation of b-catenin
Active, wild-type (wt-) ILK overexpressing podocytes
presented at nonpermissive conditions a highly prolifer-
ative phenotype in comparison to the branched nonpro-
liferative control podocytes (Fig. 1A).
Since b-catenin nuclear translocation is a key event
of phenotype programming, the subcellular localization
of b-catenin was determined by indirect immunofluo-
rescence. In contrast to the diffuse localization of b-
catenin in the cytoplasm and at cell-cell contacts in control
podocytes (Fig. 1A, A), b-catenin is localized to the nuclei
of WT-ILK overexpressing cells (Fig. 1A, B). This ILK-
induced translocation of b-catenin appears to be depen-
dent on an active kinase since the mt-ILK overexpressing
cells failed to induce nuclear translocation of b−catenin
(Fig. 1A, C). In agreement with the immunofluorescence
staining, nuclear protein levels of b-catenin in WT-ILK
overexpressing cells were induced in comparison to con-
trol and mt-ILK nuclear lysates (Fig. 1B). b-catenin pro-
tein levels in total cell lysates remained stable in all cell
lines (Fig. 3B).
ILK overexpression induces LEF-1 nuclear
colocalization with b-catenin
For effective transcriptional activity of b-catenin, the
cooperation with members of the high mobility group
transcription factors, LEF-1/TCF, is required. Therefore,
we examined the subcellular localization of LEF-1. In
contrast to control podocytes and mt-ILK overexpress-
ing cells (Fig. 1A, D and F), wild-type ILK overexpressing
cells displayed LEF-1 in a nuclear distribution (Fig. 1A,
E). Cell fractionation experiments confirmed the LEF-1
nuclear localization in WT-ILK overexpressing cells com-
pared to minimal levels found in control podocytes and
mt-ILK clones (Fig. 1B).
In order to determine whether LEF-1 colocalizes with
b-catenin in WT-ILK cells, double-labeling immunofluo-
rescence studies were performed. Figure 2 shows a signal
overlap of b-catenin and LEF-1 in cell nuclei in WT-ILK
overexpressing cells, whereas in control and mt-ILK cells
no colocalization could be found.
ILK represses P-cadherin
Activation of ILK has been reported to suppress ep-
ithelial markers like cadherins. The podocyte slit di-
aphragm was recently defined as a modified P-cadherin
containing adherens junction [26]. The ILK-dependent
P-cadherin mRNA and protein expression were exam-
ined in podocytes. A reduction in P-cadherin steady
state mRNA could be found in WT-ILK overexpressing
cells compared to control and mt-ILK cells (Fig. 3A). P-
cadherin protein levels were decreased with overexpres-
sion of WT-ILK (0.35 ± 0.32, P < 0.05 vs. CON), but not
with mt-ILK (0.63 ± 0.53, n.s. vs. CON, Fig. 3B).
Podocyte damage by puromycin/adriamycin induces an
ILK-dependent nuclear translocation of b-catenin
ILK expression and activity are increased after induc-
tion of podocyte damage with puromycin and adriamycin,
aminoglycosids known to cause selective proteinuria
[27]. However, downstream events of ILK activation in
this model have not been studied. Activation of the b-
catenin/LEF-1 pathway following podocyte injury was
examined after incubation with 5 and 10 lg/mL of
puromycin. The subcellular distribution of b-catenin was
analyzed at 0, 2, 4, 6, and 8 hours. A time- and dose-
dependent nuclear translocation of b-catenin could be
observed in response to puromycin starting as early as
2 hours after incubation with 10 lg puromycin (Fig. 4A).
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Fig. 4. Puromycin podocyte damage induces
nuclear translocation of b-catenin in an ILK-
dependent manner. (A) Podocytes grown un-
der nonpermissive conditions were treated
with 5 and 10 lg/mL puromycin. In a time
course series, a dose- and time-dependent nu-
clear translocation of b-catenin could be seen.
(B) Podocytes were stressed with 10 lg/mL
of puromycin with or without a small spe-
cific ILK-inhibitor MC-5 for 8 hours. The
puromycin induced nuclear translocation of
b-catenin could be blocked with the ILK
inhibitor, implicating ILK in b-catenin ac-
tivation during podocyte damage. In cells
overexpressing the kinase inactive form of
ILK (mt-ILK), nuclear localization of b-
catenin by puromycin was abrogated. (C) Nu-
clear localization of b-catenin in murine adri-
amycin glomerulopathy. Glomeruli of mice
with adriamycin (ADR)-induced proteinuria
(13 mg/kg body weight) showed an increase
in ILK levels (right panel: J and K). b-catenin
localization (left panels: A, D, and G) was an-
alyzed by double-immunohistochemistry with
antibodies against WT-1 (left panels: B, E, and
H). The cell type specific transcription factor
WT-1 served as a marker for podocyte nu-
clei. Control mice showed a diffuse cytoplas-
mic staining for b-catenin (A) and a nuclear
pattern of WT-1 (B) with no colocalization in
the merged picture (C). In mice with glomeru-
lar injury, b-catenin showed, in addition to
the cytoplasmic stain, a discrete nuclear signal
(D and G). The colocalization of the signal to
WT-1 (E and H) confirmed the specificity of
the staining for podocyte nuclei in proteinuric
glomeruli (F and I).
The nuclear translocation of b-catenin could be blocked
by coincubation with a small molecular inhibitor of ILK
or by overexpression of a dominant-negative ILK mutant
(Fig. 4B).
To assess the relevance of puromycin-induced b-
catenin/LEF activation in vivo, the murine model of
adriamycin-induced podocyte damage was employed.
In vehicle-injected mice, glomeruli showed a diffuse
b-catenin immunofluorescence signal (Fig. 4C). In ani-
mals with adriamycin-induced proteinuria, the glomeru-
lar b-catenin staining signal was found to colocalize with
WT-1 positive nuclei, indicating nuclear translocation of
b-catenin in podocytes of proteinuric glomeruli (Fig. 4C).
Functional consequences of ILK blockade in podocyte
damage
As ILK is involved in cell matrix interaction and
cell cycle control, the consequences of ILK inhibition
were assessed after puromycin induced podocyte dam-
age. Puromycin induced a significant reduction (48 ±
16%) in collagen matrix adhesion after 24 hours. Coincu-
bation with a small molecular inhibitor of ILK was able
to rescue podocyte matrix adhesion close to control lev-
els (85 ± 27%, Fig. 5A). Podocyte cell proliferation was
quantified using the MTT assay. Puromycin-induced cell
proliferation (128 ± 28% vs. controls, P < 0.05) could
be blocked by the ILK inhibitor (105 ± 5% vs. controls,
Fig. 5B).
To assess potential consequences of ILK blockade
in puromycin-induced podocyte damage, mRNA ex-
pression of the slit membrane associated molecules
P-cadherin, CD2ap, and FAT was quantified after
podocyte stress. Puromycin repressed mRNA levels of all
three molecules, reaching significance for P-cadherin and
CD2ap (see Fig. 5C, N = 5, P < 0.05 of puromycin vs. con-
trol). Coincubation of puromycin with the small molecu-
lar inhibitor of ILK prevented repression of mRNA levels
(see Fig. 5C).
DISCUSSION
Modification in podocyte architecture, such as cy-
toskeleton alterations, disruptions of cell-cell contacts,
and cell-matrix interaction are now considered to be crit-
ical events for the development of glomerular protein-
uria [27, 28]. Compelling evidence for this hypothesis
has recently appeared with studies on molecular anal-
ysis of hereditary nephrotic syndromes in humans and
mice. The identified molecules are primarily expressed
by podocytes, and are involved in cell-cell and cell-matrix
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Fig. 5. Functional consequences of ILK blockade in podocyte dam-
age. (A) Cell detachment. Murine podocytes were preincubated for 24
hours with 10 lg/mL puromycin and a small molecular inhibitor of ILK
MC-5. Compared to untreated controls, puromycin resulted in detach-
ment of the stressed podocytes from the collagen matrix. The small
molecular ILK inhibitor was able to maintain cell attachment (N = 4,
∗P < 0.05). (B) Cell proliferation. Podocytes treated for 24 hours with
10 lg/mL puromycin showed an increased cell proliferation as deter-
mined by MTT assay. Coincubation with the ILK inhibitor was able
to prevent the puromycin-induced proliferation (N = 5, ∗P < 0.05).
(C) ILK-dependent regulation of slit membrane associated molecules
in podocyte damage. To assess potential consequences of ILK block-
ade in puromycin-induced podocyte damage, mRNA expression of the
slit membrane associated molecules P-cadherin, CD2ap, and FAT was
quantified after podocyte stress. Ten lg/mL puromycin for 48 hours
repressed mRNA levels of all three molecules, reaching significance
for P-cadherin and CD2ap (N = 5, P < 0.05 puromycin vs. control).
Coincubation of puromycin with 5 lmol/L of the ILK inhibitor MC-5
prevented repression of mRNA levels.
interactions or are associated with the connecting cy-
toskeletal machinery [5, 29–31].
Integrin-linked kinase (ILK) has recently been iden-
tified as a cell matrix signaling molecule activated in
proteinuric diseases [20]. ILK is induced in nephrotic syn-
drome of the Finnish type and in podocyte damage in vivo
and in vitro. ILK activation in podocytes leads to phe-
notype alterations, decreased cell-matrix adhesion, and
proliferation [20]. As ILK can employ downstream ele-
ments of the Wnt signaling pathway in the epithelial cell
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Fig. 5. (Continued)
lineage [17], we hypothesized that this archetypical tran-
scriptional pathway may be instrumental in mediating al-
terations seen in podocyte damage. A recent study could
demonstrate ILK activation in tubulointerstitial damage
with repression of epithelial markers in the tubular cell
compartment [32]. The underlying signaling pathways re-
mained undefined.
In the current study, overexpression of active ILK
in podocyte induced translocation of b-catenin to the
cell nucleus, and nuclear colocalization of b-catenin with
LEF-1. As the cellular compartment defines the func-
tional role of b-catenin/LEF-1, a localization at the cell
membrane signifies a role in cell adhesion, whereas nu-
clear accumulation indicates enhanced transcription of
target genes [33].
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Podocytes are reported to undergo proliferation and
phenotype dysregulation [34] or transdifferentiation [35]
in collapsing focal segmental glomerulosclerosis. Activa-
tion of b-catenin signaling has been shown to be respon-
sible for the switch in cell phenotype in a wide spectrum
of diseases, including renal tubular damage via ATP de-
pletion [36]. The activation of this pathway in podocytes
could be responsible for the proliferative phenotype pre-
sented by wild-type ILK overexpressing cells and af-
ter puromycin stimulation in our study [20]. In contrast,
mutant ILK clones had growth arrest similar to control
podocytes. Working with gastrointestinal epithelial cells,
Novak et al found nuclear targeting and transcriptional
activation of b-catenin after ILK overexpression [17].
ILK overexpression in rat intestinal epithelial cells re-
sulted in stimulation of the G1/S cyclin-Cdk complex and
subsequent cell cycle progression [37]. The dominant-
negative mutant of ILK was shown to induce G1 cell
cycle arrest in prostate cancer cells [19]. It is intriguing
to speculate that the parallel cell cycle regulatory events
seen in diseased podocyte (i.e., collapsing focal segmen-
tal glomerulosclerosis) could at least in part being down-
stream of ILK [38, 39]. Further studies are required to
evaluate the effect of ILK activation on the complex reg-
ulation of podocyte cell cycle regulation [40].
ILK activation has been shown to decrease ma-
trix adhesion concomitant with a down-regulation of
E-cadherin [17]. Cadherins comprise a family of widely
expressed, transmembrane glycoproteins, mediating the
initiation, specificity, and maintenance of cell-cell ad-
hesion via homophilic Ca2+-dependent interactions be-
tween adjacent cells. During development, a complex
pattern of cadherin expression facilitates changes in cell
migration and morphology, influences cell fate, and con-
tributes to the establishment of tissue architecture [41].
A multimolecular complex links cadherins to the actin
cytoskeleton, increasing tensile strength of cell-cell con-
tacts. The slit diaphragm of podocytes has recently been
proposed to be a modified adherens structure contain-
ing several scaffolding proteins, including P-cadherin,
CD2ap, and FAT [2, 26]. Therefore, disturbances in the
dynamics of these molecules could lead to disruption of
this sophisticated junctional complex with severe con-
sequences to the glomerular filtration barrier. In this
study, an ILK-dependent regulation of these molecules
in podocyte damage could be shown. Detailed tran-
scriptional control mechanism for the slit membrane
molecules P-cadherin, CD2ap, and FAT have not been
evaluated and warrant further detailed studies.
The ILK-dependent b-catenin/LEF-1 activation in
transfected podocytes is paralleled by puromycin-
induced podocyte damage. Whiteside et al demonstrated
that puromycin leads to podocyte foot processes al-
terations in actin cytoskeleton and the dissociation of
podocytes from the GBM in vivo [27]. How these cell
phenotype changes were induced remained undefined.
Puromycin has been shown to induce ILK expression and
kinase activity [20]. The ILK-dependent nuclear translo-
cation of b-catenin in response to puromycin and adri-
amycin demonstrates an activation of this master switch
during podocyte damage. ILK blockade proved to be, at
least partially, protective against puromycin-induced al-
teration in podocyte adhesion, proliferation, and loss of
slit membrane components, implying considerable con-
sequences for the functional integrity of the glomerular
filtration barrier. A series of recent studies revealed loss
of viable podocytes in the urine of patients with protein-
uric renal diseases [42]. The ILK-mediated reduced cell
matrix adhesion could be a potential mechanism for the
loss of podocytes observed in many glomerulopathies.
CONCLUSION
Together, the evidence presented here indicates an
ILK-dependent podocyte phenotype regulation, which
could contribute significantly to the response seen in
glomerular disease. As this pathway is amendable to phar-
macologic intervention and could offer a fundamentally
new therapeutic strategy for proteinuria, further detailed
studies of in vivo ILK function appear justified.
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